NCT04480593View on ClinicalTrials.gov

The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions
Covid19
Interventions
DRUG

Brazilian Green Propolis Extract (EPP-AF)

Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.

OTHER

Standard care

Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).

Trial Locations (1)

41820340

Hospital Sao Rafael, Salvador

All Listed Sponsors
collaborator

Hospital Sao Rafael

OTHER

lead

D'Or Institute for Research and Education

OTHER

NCT04480593 - The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19. | Biotech Hunter | Biotech Hunter